Pfizer's RA drug Xeljanz fails to win EU panel support

04/26/2013 | PharmaTimes (U.K.) · Reuters

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended against approving Pfizer's rheumatoid arthritis drug Xeljanz, or tofacitinib. The drug improved patients' physical function and RA symptoms but it failed to sufficiently demonstrate "a consistent reduction in disease activity and structural damage to joints," the committee said. Pfizer plans to appeal the recommendation.

View Full Article in:

PharmaTimes (U.K.) · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC